{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:08:43Z","timestamp":1776874123666,"version":"3.51.2"},"reference-count":39,"publisher":"Impact Journals, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2022,6,30]]},"DOI":"10.18632\/aging.204133","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T16:55:47Z","timestamp":1655744147000},"page":"5116-5130","source":"Crossref","is-referenced-by-count":7,"title":["Risk of dialysis in patients receiving intravitreal anti\u2013vascular endothelial growth factor treatment: a population-based cohort study"],"prefix":"10.18632","volume":"14","author":[{"given":"Shun-Fa","family":"Yang","sequence":"first","affiliation":[{"name":"Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan"},{"name":"Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chen","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Chee","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Yang","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Min","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Wha","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Department of Laboratory Science and Technology, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Sheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horung","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000494298","article-title":"What are the Risk Factors for One-Year Mortality in Older Patients with Chronic Kidney Disease? An Analysis of the Cleveland Clinic CKD Registry.","volume":"14","author":"Navaneethan","year":"2019","journal-title":"Nephron"},{"key":"2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review.","volume":"38","author":"Kotwal","year":"2015","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000491708","article-title":"Incidence, Prevalence, and Duration of Chronic Kidney Disease in Taiwan: Results from a Community-Based Screening Program of 106,094 Individuals.","volume":"14","author":"Hwang","year":"2018","journal-title":"Nephron"},{"key":"4","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","article-title":"US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States.","volume":"7","author":"Gipson","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1517\/14740330802410462","article-title":"The epidemiology of drug-induced disorders: the kidney.","volume":"7","author":"Pasko","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","article-title":"Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.","volume":"9","author":"Kurtz","year":"2019","journal-title":"Kidney Int"},{"key":"7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","article-title":"The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.","volume":"8","author":"Stewart","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"8","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.18240\/ijo.2018.11.11","article-title":"One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study.","volume":"1","author":"Lai","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"9","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.2147\/DDDT.S87920","article-title":"Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.","volume":"9","author":"Wei","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2147\/OPTH.S170089","article-title":"Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review.","volume":"1","author":"Chen","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"11","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bjophthalmol-2011-301109","article-title":"The estimated prevalence and incidence of late stage age related macular degeneration in the UK.","volume":"9","author":"Rudnicka","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"12","doi-asserted-by":"publisher","first-page":"7486","DOI":"10.1038\/s41598-018-25864-0","article-title":"Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan.","volume":"8","author":"Tseng","year":"2018","journal-title":"Sci Rep"},{"key":"13","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/eye.2008.360","article-title":"The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension.","volume":"2","author":"Bahcecioglu","year":"2009","journal-title":"Eye (Lond)"},{"key":"14","first-page":"435","article-title":"Influence of intravitreal injection of bevacizumab on systemic blood pressure changes in patients with exudative form of age-related macular degeneration.","volume":"5","author":"Prostran","year":"2013","journal-title":"Hellenic J Cardiol"},{"key":"15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.","volume":"13","author":"Gordon","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00417-018-3917-9","article-title":"Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.","volume":"25","author":"Vinker","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1172\/JCI86418","article-title":"VEGF regulates local inhibitory complement proteins in the eye and kidney.","volume":"12","author":"Goult","year":"2017","journal-title":"J Clin Invest"},{"key":"18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.15171\/jnp.2017.23","article-title":"Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.","volume":"6","author":"Bastani","year":"2017","journal-title":"J Nephropathol"},{"key":"19","doi-asserted-by":"publisher","first-page":"2919080","DOI":"10.1155\/2019\/2919080","article-title":"Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury.","volume":"201","author":"Pozdzik","year":"2019","journal-title":"Case Rep Nephrol"},{"key":"20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1053\/j.ajkd.2010.11.030","article-title":"Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors.","volume":"5","author":"Delahousse","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"21","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1097\/TP.0000000000000750","article-title":"Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.","volume":"9","author":"Amer","year":"2015","journal-title":"Transplantation"},{"key":"22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ckj\/sfy060","article-title":"Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.","volume":"1","author":"Gorin","year":"2019","journal-title":"Clin Kidney J"},{"key":"23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jfma.2016.09.010","article-title":"Acute renal failure after intravitreal antivascular endothelial growth factor therapy.","volume":"11","author":"Hwang","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/1574886309666140211113635","article-title":"Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease--a possible side effect?","volume":"9","author":"Koutsandrea","year":"2014","journal-title":"Curr Drug Saf"},{"key":"25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.","volume":"12","author":"Beck","year":"2016","journal-title":"Ophthalmology"},{"key":"26","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.22086\/gmj.v0i0.1299","article-title":"Proteinuria and Renal Dysfunction after Intravitreal Injection of Bevacizumab in Patients with Diabetic Nephropathy: A Prospective Observational Study.","volume":"7","author":"Sagheb","year":"2018","journal-title":"Galen Med J"},{"key":"27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12882-019-1650-1","article-title":"Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease.","volume":"2","author":"McKay","year":"2019","journal-title":"BMC Nephrol"},{"key":"28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1167\/iovs.17-22853","article-title":"Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.","volume":"5","author":"Sun","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jdiacomp.2016.10.020","article-title":"VEGF and the diabetic kidney: More than too much of a good thing.","volume":"3","author":"Advani","year":"2017","journal-title":"J Diabetes Complications"},{"key":"30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","article-title":"Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.","volume":"12","author":"Barkmeier","year":"2021","journal-title":"Ophthalmology"},{"key":"31","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab.","volume":"3","author":"Hanley","year":"2017","journal-title":"Retina"},{"key":"32","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1021\/mp500160v","article-title":"Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.","volume":"1","author":"Yadav","year":"2014","journal-title":"Mol Pharm"},{"key":"33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/JCMA.0000000000000138","article-title":"Priority options of anti-vascular endothelial growth factor agents in wet age-related macular degeneration under the National Health Insurance Program.","volume":"8","author":"Hwang","year":"2019","journal-title":"J Chin Med Assoc"},{"key":"34","doi-asserted-by":"publisher","first-page":"4538135","DOI":"10.1155\/2020\/4538135","article-title":"Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan.","volume":"202","author":"Chen","year":"2020","journal-title":"J Ophthalmol"},{"key":"35","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.2337\/dc11-2052","article-title":"Poverty increases type 2 diabetes incidence and inequality of care despite universal health coverage.","volume":"3","author":"Cheng","year":"2012","journal-title":"Diabetes Care"},{"key":"36","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jdiacomp.2014.05.011","article-title":"Risk of hospitalization and healthcare cost associated with Diabetes Complication Severity Index in Taiwan's National Health Insurance Research Database.","volume":"2","author":"Hsiao","year":"2014","journal-title":"J Diabetes Complications"},{"key":"37","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00198-012-2185-5","article-title":"Association between osteoporosis and psoriasis: results from the Longitudinal Health Insurance Database in Taiwan.","volume":"2","author":"Lin","year":"2013","journal-title":"Osteoporos Int"},{"key":"38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/aje\/kwv445","article-title":"Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.","volume":"18","author":"Tremlett","year":"2016","journal-title":"Am J Epidemiol"},{"key":"39","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jfma.2019.08.023","article-title":"Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost.","volume":"11","author":"Yen","year":"2020","journal-title":"J Formos Med Assoc"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T16:09:29Z","timestamp":1657123769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,6,30]]}},"alternative-id":["204133","35724264"],"URL":"https:\/\/doi.org\/10.18632\/aging.204133","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]}}}